speb/financial-data huggingface dataset:
RXRX cash_flow (annual, 2025-12-31) — Change In Payable: -2616000.00
RXRX cash_flow (quarterly, 2025-12-31) — Change In Payable: 4419000.00
RXRX cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: -12351000.00
RXRX cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 1882000.00
RXRX cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: 49859000.00
RXRX cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: 20258000.00
RXRX cash_flow (annual, 2025-12-31) — Change In Receivables: 32939000.00
RXRX cash_flow (quarterly, 2025-12-31) — Change In Receivables: -836000.00
RXRX cash_flow (annual, 2025-12-31) — Change In Working Capital: 13688000.00
RXRX cash_flow (quarterly, 2025-12-31) — Change In Working Capital: 10683000.00
RXRX cash_flow (annual, 2025-12-31) — Changes In Cash: 132853000.00
RXRX cash_flow (quarterly, 2025-12-31) — Changes In Cash: 84689000.00
RXRX balance_sheet (annual, 2025-12-31) — Common Stock: 5000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Common Stock: 5000.00
RXRX balance_sheet (annual, 2025-12-31) — Common Stock Equity: 1130865000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 1130865000.00
RXRX cash_flow (annual, 2025-12-31) — Common Stock Issuance: 528864000.00
RXRX cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: 133380000.00
RXRX balance_sheet (annual, 2025-12-31) — Construction In Progress: 511000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Construction In Progress: 511000.00
RXRX income_statement (annual, 2025-12-31) — Cost Of Revenue: 70953000.00
RXRX income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 14275000.00
RXRX balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 38459000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 38459000.00
RXRX balance_sheet (annual, 2025-12-31) — Current Assets: 812845000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Current Assets: 812845000.00
RXRX balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 12663000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 12663000.00
RXRX balance_sheet (annual, 2025-12-31) — Current Debt: 9091000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Current Debt: 9091000.00
RXRX balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 21754000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 21754000.00
RXRX balance_sheet (annual, 2025-12-31) — Current Deferred Liabilities: 37605000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 37605000.00
RXRX balance_sheet (annual, 2025-12-31) — Current Deferred Revenue: 37605000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Current Deferred Revenue: 37605000.00
RXRX balance_sheet (annual, 2025-12-31) — Current Liabilities: 147707000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 147707000.00
RXRX cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 83701000.00
RXRX cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 19478000.00
RXRX cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 83701000.00
RXRX cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 19478000.00
RXRX income_statement (annual, 2025-12-31) — Diluted Average Shares: 447446109.00
RXRX income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 526719743.00
RXRX income_statement (annual, 2025-12-31) — Diluted EPS: -1.44
RXRX income_statement (quarterly, 2025-12-31) — Diluted EPS: -0.21
RXRX income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -644759000.00
RXRX income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -108122000.00
RXRX income_statement (annual, 2025-12-31) — EBIT: -643085000.00
RXRX income_statement (quarterly, 2025-12-31) — EBIT: -108112000.00
RXRX income_statement (annual, 2025-12-31) — EBITDA: -559384000.00
RXRX income_statement (quarterly, 2025-12-31) — EBITDA: -88634000.00
RXRX cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: 18044000.00
RXRX cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: 2087000.00
RXRX cash_flow (annual, 2025-12-31) — End Cash Position: 753921000.00
RXRX cash_flow (quarterly, 2025-12-31) — End Cash Position: 753921000.00
RXRX cash_flow (annual, 2025-12-31) — Financing Cash Flow: 521532000.00
RXRX cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 132006000.00
RXRX cash_flow (annual, 2025-12-31) — Free Cash Flow: -380435000.00
RXRX cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -47317000.00
RXRX cash_flow (annual, 2025-12-31) — Gain Loss On Sale Of Business: 4502000.00
RXRX cash_flow (quarterly, 2025-12-31) — Gain Loss On Sale Of Business: 0.00
RXRX balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 36717000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 36717000.00
RXRX income_statement (annual, 2025-12-31) — General And Administrative Expense: 176589000.00
RXRX income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 33657000.00
RXRX balance_sheet (annual, 2025-12-31) — Goodwill: 162158000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Goodwill: 162158000.00
RXRX balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 472061000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 472061000.00
RXRX balance_sheet (annual, 2025-12-31) — Gross PPE: 258694000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Gross PPE: 258694000.00
RXRX income_statement (annual, 2025-12-31) — Gross Profit: 3303000.00
RXRX income_statement (quarterly, 2025-12-31) — Gross Profit: 21076000.00
RXRX income_statement (annual, 2025-12-31) — Interest Expense: 1810000.00
RXRX income_statement (quarterly, 2025-12-31) — Interest Expense: -11000.00
RXRX income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 1810000.00
RXRX income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: -11000.00
RXRX income_statement (annual, 2025-12-31) — Interest Income: 22788000.00
RXRX income_statement (quarterly, 2025-12-31) — Interest Income: 6247000.00
RXRX income_statement (annual, 2025-12-31) — Interest Income Non Operating: 22788000.00
RXRX income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 6247000.00
RXRX balance_sheet (annual, 2025-12-31) — Invested Capital: 1149520000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Invested Capital: 1149520000.00
RXRX cash_flow (annual, 2025-12-31) — Investing Cash Flow: -16871000.00
RXRX cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -1244000.00
RXRX cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 528864000.00
RXRX cash_flow (quarterly, 2025-12-31) — Issuance Of Capital Stock: 133380000.00
RXRX balance_sheet (annual, 2025-12-31) — Leases: 70778000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Leases: 70778000.00
RXRX balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 46647000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 46647000.00
RXRX balance_sheet (annual, 2025-12-31) — Long Term Debt: 9564000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 9564000.00
RXRX balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 56211000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 56211000.00
RXRX cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -8425000.00
RXRX cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: -2167000.00
RXRX balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 28692000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 28692000.00
RXRX cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: -4438000.00
RXRX cash_flow (quarterly, 2025-12-31) — Net Business Purchase And Sale: 0.00
RXRX cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: 528864000.00
RXRX cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: 133380000.00
RXRX income_statement (annual, 2025-12-31) — Net Income: -644759000.00
RXRX income_statement (quarterly, 2025-12-31) — Net Income: -108122000.00
RXRX income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -644759000.00
RXRX income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -108122000.00
RXRX income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -644759000.00
RXRX income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -108121000.00
RXRX income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -644759000.00
RXRX income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -108122000.00
RXRX income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -644759000.00
RXRX income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -108122000.00
RXRX cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -644759000.00
RXRX cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -108122000.00
RXRX income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -644759000.00
RXRX income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -108121000.00
RXRX cash_flow (annual, 2025-12-31) — Net Intangibles Purchase And Sale: -2158000.00
RXRX cash_flow (quarterly, 2025-12-31) — Net Intangibles Purchase And Sale: 0.00
RXRX income_statement (annual, 2025-12-31) — Net Interest Income: 20978000.00
RXRX income_statement (quarterly, 2025-12-31) — Net Interest Income: 6258000.00
RXRX cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: -3806000.00
RXRX cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: 0.00
RXRX cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: -8425000.00
RXRX cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: -2167000.00
RXRX cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: -8425000.00
RXRX cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: -2167000.00
RXRX income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: 20978000.00
RXRX income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 6258000.00
RXRX cash_flow (annual, 2025-12-31) — Net Other Financing Charges: -3000000.00
RXRX cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: 0.00
RXRX balance_sheet (annual, 2025-12-31) — Net PPE: 169480000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Net PPE: 169480000.00
RXRX cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -6469000.00
RXRX cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -1244000.00
RXRX balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 658804000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 658804000.00
RXRX balance_sheet (annual, 2025-12-31) — Non Current Deferred Assets: 957000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Assets: 957000.00
RXRX balance_sheet (annual, 2025-12-31) — Non Current Deferred Liabilities: 137267000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 137267000.00
RXRX balance_sheet (annual, 2025-12-31) — Non Current Deferred Revenue: 114012000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Revenue: 114012000.00
RXRX balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 957000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 957000.00
RXRX balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 23255000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 23255000.00
RXRX income_statement (annual, 2025-12-31) — Normalized EBITDA: -559384000.00
RXRX income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -88634000.00
RXRX income_statement (annual, 2025-12-31) — Normalized Income: -644759000.00
RXRX income_statement (quarterly, 2025-12-31) — Normalized Income: -108122000.00
RXRX cash_flow (annual, 2025-12-31) — Operating Cash Flow: -371808000.00
RXRX cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: -46073000.00
RXRX cash_flow (annual, 2025-12-31) — Operating Gains Losses: 4502000.00
RXRX cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: -22082000.00
RXRX income_statement (annual, 2025-12-31) — Operating Income: -648132000.00
RXRX income_statement (quarterly, 2025-12-31) — Operating Income: -108334000.00
RXRX income_statement (annual, 2025-12-31) — Operating Revenue: 74256000.00
RXRX income_statement (quarterly, 2025-12-31) — Operating Revenue: 35351000.00
RXRX balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 528182693.00
RXRX balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 528182693.00
RXRX balance_sheet (annual, 2025-12-31) — Other Current Assets: 28566000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 28566000.00
RXRX balance_sheet (annual, 2025-12-31) — Other Current Borrowings: 9091000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Other Current Borrowings: 9091000.00
RXRX balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: 36717000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: 36717000.00
RXRX income_statement (annual, 2025-12-31) — Other Gand A: 176589000.00
RXRX income_statement (quarterly, 2025-12-31) — Other Gand A: 33657000.00
RXRX income_statement (annual, 2025-12-31) — Other Income Expense: -17741000.00
RXRX income_statement (quarterly, 2025-12-31) — Other Income Expense: -6025000.00
RXRX balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 309903000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 309903000.00
RXRX cash_flow (annual, 2025-12-31) — Other Non Cash Items: 53881000.00
RXRX cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 30207000.00
RXRX balance_sheet (annual, 2025-12-31) — Other Non Current Assets: 18787000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 18787000.00
RXRX balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 2080000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 2080000.00
RXRX income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: -17741000.00
RXRX income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: -6025000.00
RXRX income_statement (annual, 2025-12-31) — Other Operating Expenses: -425000.00
RXRX income_statement (quarterly, 2025-12-31) — Other Operating Expenses: -187000.00
RXRX balance_sheet (annual, 2025-12-31) — Other Properties: 158713000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Other Properties: 158713000.00
RXRX balance_sheet (annual, 2025-12-31) — Other Receivables: 24649000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Other Receivables: 24649000.00
RXRX balance_sheet (annual, 2025-12-31) — Payables: 18118000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Payables: 18118000.00
RXRX balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 56577000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 56577000.00
RXRX balance_sheet (annual, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 31771000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 31771000.00
RXRX balance_sheet (annual, 2025-12-31) — Prepaid Assets: 11742000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 11742000.00
RXRX income_statement (annual, 2025-12-31) — Pretax Income: -644895000.00
RXRX income_statement (quarterly, 2025-12-31) — Pretax Income: -108101000.00
RXRX cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 4093000.00
RXRX cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 793000.00
RXRX balance_sheet (annual, 2025-12-31) — Properties: 0.00
RXRX balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
RXRX cash_flow (annual, 2025-12-31) — Purchase Of Business: -4438000.00
RXRX cash_flow (quarterly, 2025-12-31) — Purchase Of Business: 0.00
RXRX cash_flow (annual, 2025-12-31) — Purchase Of Intangibles: -2158000.00
RXRX cash_flow (quarterly, 2025-12-31) — Purchase Of Intangibles: 0.00
RXRX cash_flow (annual, 2025-12-31) — Purchase Of Investment: -3806000.00
RXRX cash_flow (quarterly, 2025-12-31) — Purchase Of Investment: 0.00
RXRX cash_flow (annual, 2025-12-31) — Purchase Of PPE: -6469000.00
RXRX cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -1244000.00
RXRX balance_sheet (annual, 2025-12-31) — Receivables: 24649000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Receivables: 24649000.00
RXRX income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 70953000.00
RXRX income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 14275000.00
RXRX income_statement (annual, 2025-12-31) — Reconciled Depreciation: 83701000.00
RXRX income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 19478000.00
RXRX cash_flow (annual, 2025-12-31) — Repayment Of Debt: -8425000.00
RXRX cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -2167000.00
RXRX income_statement (annual, 2025-12-31) — Research And Development: 475271000.00
RXRX income_statement (quarterly, 2025-12-31) — Research And Development: 95940000.00
RXRX balance_sheet (annual, 2025-12-31) — Restricted Cash: 4594000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Restricted Cash: 4594000.00
RXRX balance_sheet (annual, 2025-12-31) — Retained Earnings: -2076002000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -2076002000.00
RXRX cash_flow (annual, 2025-12-31) — Sale Of Business: 0.00
RXRX cash_flow (annual, 2025-12-31) — Sale Of Investment: 0.00
RXRX income_statement (annual, 2025-12-31) — Selling General And Administration: 176589000.00
RXRX income_statement (quarterly, 2025-12-31) — Selling General And Administration: 33657000.00
RXRX balance_sheet (annual, 2025-12-31) — Share Issued: 528182693.00
RXRX balance_sheet (quarterly, 2025-12-31) — Share Issued: 528182693.00
RXRX cash_flow (annual, 2025-12-31) — Stock Based Compensation: 111223000.00
RXRX cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 23763000.00
RXRX balance_sheet (annual, 2025-12-31) — Stockholders Equity: 1130865000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 1130865000.00
RXRX balance_sheet (annual, 2025-12-31) — Tangible Book Value: 658804000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 658804000.00
RXRX income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
RXRX income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
RXRX income_statement (annual, 2025-12-31) — Tax Provision: -136000.00
RXRX income_statement (quarterly, 2025-12-31) — Tax Provision: 20000.00
RXRX income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.00
RXRX income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.21
RXRX balance_sheet (annual, 2025-12-31) — Total Assets: 1474130000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Total Assets: 1474130000.00
RXRX balance_sheet (annual, 2025-12-31) — Total Capitalization: 1140429000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 1140429000.00
RXRX balance_sheet (annual, 2025-12-31) — Total Debt: 77965000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Total Debt: 77965000.00
RXRX balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 1130865000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 1130865000.00
RXRX income_statement (annual, 2025-12-31) — Total Expenses: 722388000.00
RXRX income_statement (quarterly, 2025-12-31) — Total Expenses: 143685000.00
RXRX balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 343265000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 343265000.00
RXRX balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 661285000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 661285000.00
RXRX balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 195558000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 195558000.00
RXRX income_statement (annual, 2025-12-31) — Total Operating Income As Reported: -648132000.00
RXRX income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: -108334000.00
RXRX balance_sheet (annual, 2025-12-31) — Working Capital: 665138000.00
RXRX balance_sheet (quarterly, 2025-12-31) — Working Capital: 665138000.00
RXRX income_statement (quarterly, 2026-03-31) — +Operating Expense: 122316000.00
RXRX income_statement (quarterly, 2026-03-31) — +Total Revenue: 6301000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 20348000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 3191608000.00
RXRX cash_flow (quarterly, 2026-03-31) — Asset Impairment Charge: 0.00
RXRX income_statement (quarterly, 2026-03-31) — Basic Average Shares: 529303984.00
RXRX income_statement (quarterly, 2026-03-31) — Basic EPS: -0.22
RXRX cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 753921000.00
RXRX cash_flow (quarterly, 2026-03-31) — Capital Expenditure: -338000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 55929000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Capital Stock: 5000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 654473000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 654473000.00
RXRX cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: -3470000.00
RXRX cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -338000.00
RXRX cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -81101000.00
RXRX cash_flow (quarterly, 2026-03-31) — Change In Account Payable: 2070000.00
RXRX cash_flow (quarterly, 2026-03-31) — Change In Accrued Expense: -17721000.00
RXRX cash_flow (quarterly, 2026-03-31) — Change In Other Current Liabilities: -4652000.00
RXRX cash_flow (quarterly, 2026-03-31) — Change In Other Working Capital: -2248000.00
RXRX cash_flow (quarterly, 2026-03-31) — Change In Payable: 2070000.00
RXRX cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -15651000.00
RXRX cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: 0.00
RXRX cash_flow (quarterly, 2026-03-31) — Change In Receivables: 14746000.00
RXRX cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -7805000.00
RXRX cash_flow (quarterly, 2026-03-31) — Changes In Cash: -84909000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Common Stock: 5000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 1024769000.00
RXRX cash_flow (quarterly, 2026-03-31) — Common Stock Issuance: 0.00
RXRX income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 12490000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 39639000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Current Assets: 709557000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 13087000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Current Debt: 9265000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 22352000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Current Deferred Liabilities: 32794000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Current Deferred Revenue: 32794000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 129699000.00
RXRX cash_flow (quarterly, 2026-03-31) — Deferred Income Tax: -4597000.00
RXRX cash_flow (quarterly, 2026-03-31) — Deferred Tax: -4597000.00
RXRX cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 19673000.00
RXRX cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 19673000.00
RXRX income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 529303984.00
RXRX income_statement (quarterly, 2026-03-31) — Diluted EPS: -0.22
RXRX income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -117504000.00
RXRX income_statement (quarterly, 2026-03-31) — EBIT: -121758000.00
RXRX income_statement (quarterly, 2026-03-31) — EBITDA: -102085000.00
RXRX cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: -3832000.00
RXRX cash_flow (quarterly, 2026-03-31) — End Cash Position: 665180000.00
RXRX cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: -3470000.00
RXRX cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -81439000.00
RXRX cash_flow (quarterly, 2026-03-31) — Gain Loss On Sale Of Business: 0.00
RXRX balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: 26662000.00
RXRX income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 34591000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Goodwill: 160170000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 454243000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Gross PPE: 157321000.00
RXRX income_statement (quarterly, 2026-03-31) — Gross Profit: -6189000.00
RXRX income_statement (quarterly, 2026-03-31) — Interest Expense: 350000.00
RXRX income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 350000.00
RXRX income_statement (quarterly, 2026-03-31) — Interest Income: 5963000.00
RXRX income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 5963000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Invested Capital: 1041215000.00
RXRX cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -338000.00
RXRX cash_flow (quarterly, 2026-03-31) — Issuance Of Capital Stock: 0.00
RXRX balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 42842000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 7181000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 50023000.00
RXRX cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -2208000.00
RXRX cash_flow (quarterly, 2026-03-31) — Net Business Purchase And Sale: 0.00
RXRX cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: 0.00
RXRX income_statement (quarterly, 2026-03-31) — Net Income: -117504000.00
RXRX income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -117504000.00
RXRX income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -117504000.00
RXRX income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -117504000.00
RXRX income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -117504000.00
RXRX cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -117504000.00
RXRX income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -117504000.00
RXRX cash_flow (quarterly, 2026-03-31) — Net Intangibles Purchase And Sale: -80000.00
RXRX income_statement (quarterly, 2026-03-31) — Net Interest Income: 5613000.00
RXRX cash_flow (quarterly, 2026-03-31) — Net Investment Purchase And Sale: 0.00
RXRX cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: -2208000.00
RXRX cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: -2208000.00
RXRX income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 5613000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Net PPE: 157321000.00
RXRX cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -258000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 570526000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Assets: 957000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 133006000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Revenue: 114723000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 957000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 18283000.00
RXRX income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -102085000.00
RXRX income_statement (quarterly, 2026-03-31) — Normalized Income: -117504000.00
RXRX cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -81101000.00
RXRX income_statement (quarterly, 2026-03-31) — Operating Income: -128505000.00
RXRX income_statement (quarterly, 2026-03-31) — Operating Revenue: 6301000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 530628653.00
RXRX balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 24246000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Other Current Borrowings: 9265000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: 26662000.00
RXRX income_statement (quarterly, 2026-03-31) — Other Gand A: 34591000.00
RXRX income_statement (quarterly, 2026-03-31) — Other Income Expense: 784000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 294073000.00
RXRX cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 6917000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 17444000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 2025000.00
RXRX income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 784000.00
RXRX income_statement (quarterly, 2026-03-31) — Other Operating Expenses: -171000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Other Properties: 157321000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Other Receivables: 13585000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Payables: 20348000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 59987000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 14566000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 11742000.00
RXRX income_statement (quarterly, 2026-03-31) — Pretax Income: -122108000.00
RXRX cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: -1262000.00
RXRX cash_flow (quarterly, 2026-03-31) — Purchase Of Business: 0.00
RXRX cash_flow (quarterly, 2026-03-31) — Purchase Of Intangibles: -80000.00
RXRX cash_flow (quarterly, 2026-03-31) — Purchase Of Investment: 0.00
RXRX cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -258000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Receivables: 13585000.00
RXRX income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 12490000.00
RXRX income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 19673000.00
RXRX cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -2208000.00
RXRX income_statement (quarterly, 2026-03-31) — Research And Development: 87896000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Restricted Cash: 5511000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -2193506000.00
RXRX income_statement (quarterly, 2026-03-31) — Selling General And Administration: 34591000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Share Issued: 530628653.00
RXRX cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 22215000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 1024769000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 570526000.00
RXRX income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
RXRX income_statement (quarterly, 2026-03-31) — Tax Provision: -4604000.00
RXRX income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.04
RXRX balance_sheet (quarterly, 2026-03-31) — Total Assets: 1339522000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 1031950000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Total Debt: 72375000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 1024769000.00
RXRX income_statement (quarterly, 2026-03-31) — Total Expenses: 134806000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 314753000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 629965000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 185054000.00
RXRX income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: -128505000.00
RXRX balance_sheet (quarterly, 2026-03-31) — Working Capital: 579858000.00
RXST income_statement (annual, 2021-12-31) — Basic Average Shares: 13625044.00
RXST income_statement (annual, 2021-12-31) — Basic EPS: -3.57
RXST balance_sheet (annual, 2021-12-31) — Current Accrued Expenses: 319000.00
RXST balance_sheet (annual, 2021-12-31) — Derivative Product Liabilities: 0.00
RXST income_statement (annual, 2021-12-31) — Diluted Average Shares: 13625044.00
RXST income_statement (annual, 2021-12-31) — Diluted EPS: -3.57
RXST cash_flow (annual, 2021-12-31) — Gain Loss On Investment Securities: -7735000.00
RXST cash_flow (annual, 2021-12-31) — Gain Loss On Sale Of PPE: 0.00
RXST income_statement (annual, 2021-12-31) — Gain On Sale Of Ppe: 0.00
RXST income_statement (annual, 2021-12-31) — Gain On Sale Of Security: 7735000.00
RXST balance_sheet (annual, 2021-12-31) — Interest Payable: 319000.00
RXST balance_sheet (annual, 2021-12-31) — Long Term Debt: 39760000.00
RXST balance_sheet (annual, 2021-12-31) — Net Debt: 15399000.00
RXST cash_flow (annual, 2021-12-31) — Operating Gains Losses: -7735000.00
RXST income_statement (annual, 2021-12-31) — Other Income Expense: 7735000.00
RXST cash_flow (annual, 2021-12-31) — Other Non Cash Items: 493000.00
RXST income_statement (annual, 2021-12-31) — Otherunder Preferred Stock Dividend: 0.00
RXST balance_sheet (annual, 2021-12-31) — Prepaid Assets: 4069000.00
RXST cash_flow (annual, 2021-12-31) — Proceeds From Stock Option Exercised: 790000.00
RXST cash_flow (annual, 2021-12-31) — Sale Of PPE: 0.00
RXST income_statement (annual, 2022-12-31) — +Operating Expense: 84646000.00
RXST income_statement (annual, 2022-12-31) — +Total Revenue: 49005000.00
RXST balance_sheet (annual, 2022-12-31) — Accounts Payable: 2595000.00
RXST balance_sheet (annual, 2022-12-31) — Accounts Receivable: 10956000.00
RXST balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -19898000.00
RXST balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 636001000.00
RXST cash_flow (annual, 2022-12-31) — Amortization Of Securities: -1405000.00
RXST income_statement (annual, 2022-12-31) — Basic Average Shares: 27661982.00
RXST income_statement (annual, 2022-12-31) — Basic EPS: -2.41
RXST cash_flow (annual, 2022-12-31) — Beginning Cash Position: 25172000.00
RXST cash_flow (annual, 2022-12-31) — Capital Expenditure: -2393000.00
RXST balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 4826000.00
RXST balance_sheet (annual, 2022-12-31) — Capital Stock: 28000.00
RXST balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 11834000.00
RXST balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 105802000.00
RXST cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 6332000.00
RXST cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: 39950000.00
RXST cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: -58850000.00
RXST cash_flow (annual, 2022-12-31) — Change In Account Payable: 635000.00
RXST cash_flow (annual, 2022-12-31) — Change In Accrued Expense: 4813000.00
RXST cash_flow (annual, 2022-12-31) — Change In Inventory: -7555000.00
RXST cash_flow (annual, 2022-12-31) — Change In Payable: 635000.00
RXST cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: 5448000.00
RXST cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: 789000.00
RXST cash_flow (annual, 2022-12-31) — Change In Receivables: -6094000.00
RXST cash_flow (annual, 2022-12-31) — Change In Working Capital: -7412000.00
RXST cash_flow (annual, 2022-12-31) — Changes In Account Receivables: -6094000.00
RXST cash_flow (annual, 2022-12-31) — Changes In Cash: -12568000.00
RXST balance_sheet (annual, 2022-12-31) — Common Stock: 28000.00
RXST balance_sheet (annual, 2022-12-31) — Common Stock Equity: 89902000.00
RXST cash_flow (annual, 2022-12-31) — Common Stock Issuance: 7828000.00
RXST balance_sheet (annual, 2022-12-31) — Construction In Progress: 1331000.00
RXST income_statement (annual, 2022-12-31) — Cost Of Revenue: 27677000.00
RXST balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 455000.00
RXST balance_sheet (annual, 2022-12-31) — Current Assets: 134555000.00
RXST balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 1970000.00
RXST balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 1970000.00
RXST balance_sheet (annual, 2022-12-31) — Current Deferred Liabilities: 1348000.00
RXST balance_sheet (annual, 2022-12-31) — Current Deferred Revenue: 1348000.00
RXST balance_sheet (annual, 2022-12-31) — Current Liabilities: 17237000.00
RXST cash_flow (annual, 2022-12-31) — Depreciation: 4022000.00
RXST cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 4022000.00
RXST cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 4022000.00
RXST income_statement (annual, 2022-12-31) — Diluted Average Shares: 27661982.00
RXST income_statement (annual, 2022-12-31) — Diluted EPS: -2.41
RXST income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -66756000.00
RXST income_statement (annual, 2022-12-31) — EBIT: -61801000.00
RXST income_statement (annual, 2022-12-31) — EBITDA: -57779000.00
RXST cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: -9000.00
RXST cash_flow (annual, 2022-12-31) — End Cash Position: 12595000.00
RXST cash_flow (annual, 2022-12-31) — Financing Cash Flow: 6332000.00
RXST balance_sheet (annual, 2022-12-31) — Finished Goods: 6408000.00
RXST cash_flow (annual, 2022-12-31) — Free Cash Flow: -61243000.00
RXST balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: -95000.00
RXST balance_sheet (annual, 2022-12-31) — Gross PPE: 33979000.00
RXST income_statement (annual, 2022-12-31) — Gross Profit: 21328000.00
RXST cash_flow (annual, 2022-12-31) — Income Tax Paid Supplemental Data: 3000.00
RXST income_statement (annual, 2022-12-31) — Interest Expense: 4946000.00
RXST income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 4946000.00
RXST income_statement (annual, 2022-12-31) — Interest Income: 1517000.00
RXST income_statement (annual, 2022-12-31) — Interest Income Non Operating: 1517000.00
RXST cash_flow (annual, 2022-12-31) — Interest Paid Supplemental Data: 4257000.00
RXST balance_sheet (annual, 2022-12-31) — Interest Payable: 455000.00
RXST balance_sheet (annual, 2022-12-31) — Inventories Adjustments Allowances: -634000.00
RXST balance_sheet (annual, 2022-12-31) — Inventory: 14835000.00
RXST balance_sheet (annual, 2022-12-31) — Invested Capital: 130071000.00
RXST cash_flow (annual, 2022-12-31) — Investing Cash Flow: 39950000.00
RXST cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 7828000.00
RXST cash_flow (annual, 2022-12-31) — Issuance Of Debt: 0.00
RXST balance_sheet (annual, 2022-12-31) — Leases: 11206000.00
RXST balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 2856000.00
RXST balance_sheet (annual, 2022-12-31) — Long Term Debt: 40169000.00
RXST balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 43025000.00
RXST cash_flow (annual, 2022-12-31) — Long Term Debt Issuance: 0.00
RXST cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -121000.00
RXST balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 15420000.00
RXST cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 7828000.00
RXST balance_sheet (annual, 2022-12-31) — Net Debt: 28335000.00
RXST income_statement (annual, 2022-12-31) — Net Income: -66756000.00
RXST income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -66756000.00
RXST income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -66756000.00
RXST income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -66756000.00
RXST income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -66756000.00
RXST cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -66756000.00
RXST income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -66756000.00
RXST income_statement (annual, 2022-12-31) — Net Interest Income: -3429000.00
RXST cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: 42343000.00
RXST cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -121000.00
RXST cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -121000.00
RXST income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: -3429000.00
RXST cash_flow (annual, 2022-12-31) — Net Other Financing Charges: -1375000.00
RXST balance_sheet (annual, 2022-12-31) — Net PPE: 14081000.00
RXST cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -2393000.00
RXST balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 89902000.00
RXST income_statement (annual, 2022-12-31) — Normalized EBITDA: -57779000.00
RXST income_statement (annual, 2022-12-31) — Normalized Income: -66756000.00
RXST cash_flow (annual, 2022-12-31) — Operating Cash Flow: -58850000.00
RXST income_statement (annual, 2022-12-31) — Operating Income: -63318000.00
RXST income_statement (annual, 2022-12-31) — Operating Revenue: 49005000.00
RXST balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 28268389.00
RXST balance_sheet (annual, 2022-12-31) — Other Current Assets: 2962000.00
RXST balance_sheet (annual, 2022-12-31) — Other Current Liabilities: 2332000.00
RXST balance_sheet (annual, 2022-12-31) — Other Equity Adjustments: -95000.00
RXST cash_flow (annual, 2022-12-31) — Other Non Cash Items: 552000.00
RXST balance_sheet (annual, 2022-12-31) — Other Non Current Assets: 1528000.00
RXST balance_sheet (annual, 2022-12-31) — Other Properties: 6022000.00
RXST balance_sheet (annual, 2022-12-31) — Other Short Term Investments: 93968000.00
RXST balance_sheet (annual, 2022-12-31) — Payables: 2595000.00
RXST balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 3050000.00
RXST balance_sheet (annual, 2022-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 8537000.00
RXST balance_sheet (annual, 2022-12-31) — Preferred Stock: 0.00
RXST income_statement (annual, 2022-12-31) — Pretax Income: -66747000.00
RXST cash_flow (annual, 2022-12-31) — Proceeds From Stock Option Exercised: 1778000.00
RXST balance_sheet (annual, 2022-12-31) — Properties: 0.00
RXST cash_flow (annual, 2022-12-31) — Provisionand Write Offof Assets: 752000.00
RXST cash_flow (annual, 2022-12-31) — Purchase Of Investment: -212657000.00
RXST cash_flow (annual, 2022-12-31) — Purchase Of PPE: -2393000.00
RXST balance_sheet (annual, 2022-12-31) — Raw Materials: 6494000.00
RXST balance_sheet (annual, 2022-12-31) — Receivables: 10956000.00
RXST income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 27677000.00
RXST income_statement (annual, 2022-12-31) — Reconciled Depreciation: 4022000.00
RXST cash_flow (annual, 2022-12-31) — Repayment Of Debt: -121000.00
RXST income_statement (annual, 2022-12-31) — Research And Development: 25981000.00
RXST balance_sheet (annual, 2022-12-31) — Retained Earnings: -546032000.00
RXST cash_flow (annual, 2022-12-31) — Sale Of Investment: 255000000.00
RXST income_statement (annual, 2022-12-31) — Selling General And Administration: 58665000.00
RXST balance_sheet (annual, 2022-12-31) — Share Issued: 28268389.00
RXST income_statement (annual, 2022-12-31) — Special Income Charges: 0.00
RXST cash_flow (annual, 2022-12-31) — Stock Based Compensation: 11397000.00
RXST balance_sheet (annual, 2022-12-31) — Stockholders Equity: 89902000.00
RXST balance_sheet (annual, 2022-12-31) — Tangible Book Value: 89902000.00
RXST income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 0.00
RXST income_statement (annual, 2022-12-31) — Tax Provision: 9000.00
RXST income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.00
RXST balance_sheet (annual, 2022-12-31) — Total Assets: 150164000.00
RXST balance_sheet (annual, 2022-12-31) — Total Capitalization: 130071000.00
RXST balance_sheet (annual, 2022-12-31) — Total Debt: 44995000.00
RXST balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 89902000.00
RXST income_statement (annual, 2022-12-31) — Total Expenses: 112323000.00
RXST balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 60262000.00
RXST balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 15609000.00
RXST balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 43025000.00
RXST income_statement (annual, 2022-12-31) — Total Operating Income As Reported: -63318000.00
RXST income_statement (annual, 2022-12-31) — Total Unusual Items: 0.00
RXST income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: 0.00
RXST balance_sheet (annual, 2022-12-31) — Work In Process: 2567000.00
RXST balance_sheet (annual, 2022-12-31) — Working Capital: 117318000.00
RXST income_statement (annual, 2023-12-31) — +Operating Expense: 103850000.00
RXST income_statement (annual, 2023-12-31) — +Total Revenue: 89077000.00
RXST balance_sheet (annual, 2023-12-31) — Accounts Payable: 3863000.00
RXST balance_sheet (annual, 2023-12-31) — Accounts Receivable: 20281000.00
RXST balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -22698000.00
RXST balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 754971000.00
RXST cash_flow (annual, 2023-12-31) — Amortization Of Securities: -6122000.00
RXST income_statement (annual, 2023-12-31) — Basic Average Shares: 34455111.00
RXST income_statement (annual, 2023-12-31) — Basic EPS: -1.41
RXST cash_flow (annual, 2023-12-31) — Beginning Cash Position: 12595000.00
RXST cash_flow (annual, 2023-12-31) — Capital Expenditure: -4814000.00
RXST balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 3012000.00
RXST balance_sheet (annual, 2023-12-31) — Capital Stock: 36000.00
RXST balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 9692000.00
RXST balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 127182000.00
RXST cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: 61524000.00
RXST cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: -22129000.00
RXST cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: -41593000.00
RXST cash_flow (annual, 2023-12-31) — Change In Account Payable: 1250000.00
RXST cash_flow (annual, 2023-12-31) — Change In Accrued Expense: 2314000.00
RXST cash_flow (annual, 2023-12-31) — Change In Inventory: -2749000.00
RXST cash_flow (annual, 2023-12-31) — Change In Payable: 1250000.00
RXST cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: 3564000.00
RXST cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: -397000.00
RXST cash_flow (annual, 2023-12-31) — Change In Receivables: -9325000.00
RXST cash_flow (annual, 2023-12-31) — Change In Working Capital: -8907000.00
RXST cash_flow (annual, 2023-12-31) — Changes In Account Receivables: -9325000.00
RXST cash_flow (annual, 2023-12-31) — Changes In Cash: -2198000.00
RXST balance_sheet (annual, 2023-12-31) — Common Stock: 36000.00
RXST balance_sheet (annual, 2023-12-31) — Common Stock Equity: 160362000.00
RXST cash_flow (annual, 2023-12-31) — Common Stock Issuance: 105957000.00
RXST balance_sheet (annual, 2023-12-31) — Construction In Progress: 2335000.00
RXST income_statement (annual, 2023-12-31) — Cost Of Revenue: 35312000.00
RXST balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 0.00
RXST balance_sheet (annual, 2023-12-31) — Current Assets: 168407000.00
RXST balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 1801000.00
RXST balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 1801000.00